Altogether, molecular monitoring of the TERT breakpoint in the two compartments (peripheral blood and BM) retrospectively detected the neuroblastoma relapse in patient P4 earlier and more accurately than (i) MRI and 123I-mIBG clinical imaging and BM GD2 immunocytology (considered the gold standard for neuroblastoma monitoring in Europe and North America) and (ii) the previously reported cfDNA-based ALK copy number assessment (6). This evidence concerns the gene ALK and neuroblastoma.